कृपया अन्य खोज का प्रयास करें
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Iain Gladstone Ross | 69 | 2021 | Executive Chairman |
Michael John Owen | 72 | 2015 | Independent Non-Executive Director |
Martin Charles Walton | 58 | 2022 | Independent Non-Executive Director |
Barbara Regina Staehelin | 60 | 2021 | Senior Independent Non-Executive Director |
Giuseppe Battaglia | - | 2023 | Member of Scientific Advisory Board |
Kenneth W. Witwer | - | 2023 | Member of Scientific Advisory Board |
Stefano Pluchino | - | 2021 | Chair of the Scientific Advisory Board |
Bernd Giebel | - | 2023 | Member of Scientific Advisory Board |
Edit I. Buzas | - | 2023 | Member of Scientific Advisory Board |
John Michael Hawkins | 56 | 2021 | Company Secretary, CFO & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है